MAPT and Alzheimer disease: Increases in plasma p-tau 181 have also been found to differentiate Alzheimer’s disease from non-Alzheimer’s disease and predict cognitive decline during the preclinical and prodromal stages of Alzheimer’s disease.16,31,42,43 Interestingly, p-tau 217 concentrations in CSF and plasma have been found to be more sensitive than p-tau 181 in detecting Alzheimer’s disease during preclinical stages.20,44,45 To determine whether the localizations of p-tau 181 and p-tau 217 are similar, brain sections from 6- and 24-month-old AppNLGF, AppNL and WT mice were stained with an antibody against p-tau 181.